The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Exploring the potential of fruquintinib in earlier treatment settings
Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the potential for moving fruquintinib into earlier treatment settings. As an oral agent, fruquintinib offers advantages for combination therapies. There is significant interest in combining it with agents such as capecitabine for maintenance therapy and immune checkpoint inhibitors. Small Phase II studies (ChiCTR2200059280) in China have shown promising results, and further large-scale studies in the United States and other countries are anticipated to validate these findings. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Elevar Therapeutics (Inst); Elevation Oncology; General Electric; GlaxoSmithKline; Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology; Merck (Inst); Merck Serono; natera; Pfizer; Pfizer (Inst); Seagen
